Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Enzalutamide
Drug ID BADD_D00775
Description Enzalutamide is an androgen receptor inhibitor for the treatment of castration-resistant prostate cancer. FDA approved on August 31, 2012.
Indications and Usage Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
Marketing Status Prescription
ATC Code L02BB04
DrugBank ID DB08899
KEGG ID D10218
MeSH ID C540278
PubChem ID 15951529
TTD Drug ID D0QK5X
NDC Product Code 54893-0044; 55111-976; 0469-0625; 65392-2209; 68554-0106; 65015-876; 62128-0388; 65129-1376; 59285-018; 42385-733; 0469-0725; 11014-0003; 15308-1121; 0469-0125
Synonyms enzalutamide | 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-benzamide | enzalutamide D3 | HC-1119 | HC 1119 | 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide | Xtandi | MDV 3100 | MDV3100 | MDV-3100
Chemical Information
Molecular Formula C21H16F4N4O2S
CAS Registry Number 915087-33-1
SMILES CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Dermatitis allergic10.01.03.014; 23.03.04.003--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.001471%
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.0020.008090%Not Available
Disorientation19.13.01.002; 17.02.05.0150.016916%Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.002--
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.0030.164014%
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.0010.013239%
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia17.02.07.003; 07.14.03.0010.038981%
Dyskinesia17.01.02.006--
Dyspepsia07.01.02.0010.018387%
Dysphagia07.01.06.0030.211821%
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.004--
Dyspnoea22.02.01.004; 02.01.03.002--
Dyspnoea exertional02.01.03.003; 22.02.01.0050.005884%Not Available
Dysuria20.02.02.0020.006619%
Ear infection11.01.05.001; 04.03.01.006--Not Available
Ear pain04.03.01.0030.002206%
Eating disorder14.03.01.008; 19.09.01.0080.008826%Not Available
Eczema23.03.04.006--
Electrocardiogram QT prolonged13.14.05.004--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 23 Pages